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Abstract 
Background and objectives 
The Effect of a Reduction in Glomerular Filtration Rate after Nephrectomy on Arterial 
Stiffness and Central Hemodynamics (EARNEST) was a multi-center, prospective, controlled 
study designed to investigate the associations of an isolated reduction in kidney function on 
blood pressure and arterial hemodynamics. 
Design, setting, participants and measurements 
Prospective living kidney donors and healthy controls who fulfilled criteria for donation were 
recruited from centers with expertise in vascular research. Participants underwent office and 
ambulatory blood pressure measurement, assessment of arterial stiffness and biochemical tests 
at baseline and 12 months. 
Results 
A total of 469 participants were recruited and 306 (168 donors and 138 controls) were followed 
up at 12 months. In the donor group, mean eGFR was 27 mL/min/1.73m2 lower than baseline 
at 12 months.  
Compared to baseline, at 12 months the mean within group difference in ambulatory day 
systolic blood pressure in donors was 0.1mmHg (95% CI -1.7, 1.9) and 0.6mmHg (95% CI -
0.7, 2.0) in controls. The between group difference was not significant, -0.5mmHg (95% CI -
2.8, 1.7), p=0.62. The mean within group difference in pulse wave velocity in donors was 
0.3m/s (95% CI 0.1, 0.4) and 0.2m/s (95% CI -0.0, 0.4) in controls. The between group 
difference was also not significant, 0.1m/s (95% CI -0.2, 0.3) p=0.49. 
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 Conclusions 
Changes in ambulatory peripheral blood pressure and pulse wave velocity in kidney donors at 
12 months after nephrectomy were small and not different from controls.   
Keywords (5-7): Blood pressure; Arterial stiffness; Hypertension; Living kidney donors; 
Chronic kidney disease; Pulse wave velocity. 
 
 
 
 
 
 
 
 
 
 
 
 
 
3 
 
Introduction  
Chronic kidney disease (CKD) is a major risk factor for cardiovascular disease; there is a 
graded association, independent of multiple cardiovascular risk factors, between glomerular 
filtration rate (GFR) and cardiovascular risk.(1) In early stage CKD, mortality from 
cardiovascular events is more likely than the need for kidney replacement therapy.(2) 
Hypertension, increased arterial stiffness, chronic inflammation and uremic toxins are thought 
to be key mediators of the higher cardiovascular risk.(3) In patients with end stage kidney 
disease (ESKD) increased arterial stiffness as measured by pulse wave velocity is an 
independent predictor of mortality.(4)  Increased arterial stiffness is also highly prevalent in 
earlier stages of CKD.(5) It is not clear whether increased blood pressure and arterial stiffness 
in CKD are direct consequences of the reduced GFR or result from multiple co-morbid 
conditions that tend to accompany CKD.  
Living kidney donors provide an opportunity to prospectively examine the cardiovascular 
consequences of a reduction in kidney function without the confounding effects of co-morbid 
disease. In the long term, kidney donors lose approximately 30% of their baseline GFR and 
consequently over 65% have a GFR consistent with stages 2 and 3 CKD.(6) They also have 
similar biochemical abnormalities to patients with CKD.(7)  While the risk of ESKD after 
nephrectomy is higher compared to controls, absolute risk over a 15 year period, remains 
low.(8, 9) To date, however, most studies of kidney donors have not shown a higher 
cardiovascular risk or mortality.(10, 11) Only one study has shown higher cardiovascular 
mortality compared to controls, which occurred later over a 10 year follow-up period.(8) The 
aim of this study was to determine the effect of the reduction in kidney function that occurs 
after kidney donation on arterial stiffness and blood pressure in a sample large enough to detect 
small differences.  
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Materials and Methods 
Study design 
The EARNEST (Effect of A Reduction in glomerular filtration rate after NEphrectomy on 
arterial STiffness and central hemodynamics) study was a prospective multicenter UK cohort 
study.  We aimed to recruit 440 controls and 440 donors over a two year period from seven 
centers recognised for performing high numbers of living kidney transplants within the UK. 
Recruitment began in April 2012; the last follow up patient was studied in May 2016. 
Recruitment was terminated in May 2015 on pragmatic and financial grounds. This was 
principally due to unanticipated large numbers of recruited participants dropping out at follow 
up. 
Study population 
The inclusion and exclusion criteria for donors and controls were in accordance with national 
guidelines disseminated by the Joint Working Party of the British Transplantation Society and 
the Renal Association for living kidney donors.(12) Both donors and controls had to be deemed 
fit to donate a kidney.  
Most healthy controls were individuals undergoing workup for donation but who were 
ultimately unable to donate due to factors such as immunological mismatch or recipient illness. 
Alternatively, donor-related family members or volunteers donating blood at local blood 
donation centers were recruited.  
Study protocol 
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All participants were investigated at baseline (less than 6 weeks prior to nephrectomy for 
prospective living kidney donors) and at 12 months. A full illustrated and detailed protocol has 
previously been published with a summary presented below.(13) 
1. Blood pressure measurement: Office blood pressure was measured three times, from 
the non-dominant arm after 5 minutes of rest, using a validated automated device. 
Blood pressure was taken in both a sitting and supine position. Participants underwent 
24hr ambulatory blood pressure monitoring using the Mobilo-O-Graph NG; IEM 
(Stolberg, Germany).(14)  Blood pressure recordings were taken every 30 minutes 
between the hours of 0800-2200, and every 60 minutes between 2201 and 0759.(15, 
16) 
 
2. Pulse wave velocity: Pulse wave velocity was measured using SphygmoCor (Atcor 
Medical, Sydney, Australia) by trained personnel after asking the participant to lie 
supine for 15 minutes. Repeated uniform pressure waveforms were acquired from both 
the carotid and femoral artery using a high fidelity micromanometer (SPC-301; Millar 
Instruments, Houston, TX).(17) A 3 lead electrocardiogram was used to determine the 
time between the R wave and the foot of the pulse at each respective site as previously 
described.(18) Arterial path distance was inferred using the distance from the sternal 
notch to the femoral pulse subtracted by the distance between the sternal notch and the 
carotid pulse. (19) 
 
3. Pulse wave analysis: Using the SphygmoCor device; arterial pressure waveforms 
were obtained from which central waveforms can be calculated. Central blood pressure 
and augmentation index (AIx) were calculated using transfer functions as previously 
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described.(15, 20) Augmentation index is the augmentation pressure from the aortic 
waveform expressed as a percentage of pulse pressure, see Figure 1. 
 
4. Assessment of glomerular filtration rate: Glomerular filtration rate was determined 
in all participants using standardised creatinine assays and the Chronic Kidney Disease 
Epidemiology Collaboration (CKD-EPI) creatinine 2009 equation.(21, 22) A subset of 
living kidney donors underwent isotopic GFR measurement using clearance of 51Cr-
EDTA at both baseline and follow up.(23, 24)  
 
5. Blood and urine: Biochemistry measurements included serum creatinine, calcium, 
albumin, phosphate and uric acid and urinary albumin: creatinine ratio.  
Primary outcomes 
1. Mean change in ambulatory systolic blood pressure. 
2. Mean change in pulse wave velocity. 
Statement of ethics 
Ethical approval for the main study was obtained in February 2013 from the South Cambridge 
Regional Ethics Committee (Integrated Research Application System Reference: 118797, 
Research Ethics Committee approval number 13/EE/0015). The EARNEST sub study (CRIB-
DONOR) commenced in 2011, ethical approval was obtained from the West Midlands 
Research Ethics Committee. All participants underwent informed consent in keeping with the 
principles set out by the Declaration of Helsinki. 
Power calculations and sample size 
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Using data from previous studies, the standard deviation of the within-patient changes was 
assumed to be 10 mmHg for blood pressure and 1.0 m/s for pulse wave velocity.(17, 25) A 
sample size of 800 participants (400 subjects per group) was planned in order to provide 80% 
power to detect a difference of 2.2mmHg in systolic pressure or 0.22 m/s in pulse wave velocity 
using a 2-sided t-test at the 2.5% significance level.  Values for a sample size of 400 participants 
(200 subjects per group) have 92% power to detect a difference of 4 mmHg for systolic blood 
pressure and 0.4 m/s for pulse wave velocity, allowing for 15% loss to follow-up at a 
significance level of 5%.   
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Statistical analysis 
Statistical analysis was performed using Stata statistical software (release 15. StataCorp LCC, 
College Station, TX). Continuous variables at baseline and 12 months were compared using 
independent t-tests. Categorical variables were compared using Chi squared tests. A paired 
samples t test was used to estimate the mean change and 95% confidence interval between 
baseline and follow-up in each group (within-group change). Change from baseline to 12 
months was calculated for both donors and controls. An independent t test was used to estimate 
the mean change and 95% confidence interval between within-group change in donors and 
within-group change in controls (between-group change). Carotid-femoral pulse wave velocity 
was adjusted for average mean arterial pressure and average supine heart rate using 
unstandardized residuals calculated from a linear regression model. In supplementary analyses, 
we used multivariable linear regression to account for factors which may have confounded the 
relationship between kidney donation and change in pulse wave velocity (age, sex and smoking 
status). A p-value of <0.05 was considered significant, no adjustments were made for multiple 
comparisons. Data presented includes subjects who returned for follow up. We dealt with 
missing data by performing a complete case analysis. Further sub-analysis of those who 
remained in the study compared to those who were lost to follow up are detailed in supplement 
Table S1, S2 and S3.   
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Results  
Follow up and events  
A total of 469 participants were recruited; 20 were excluded as they lacked the minimal data 
set required for analysis and two were found to be ineligible after the initial visit (see Figure 
2). Recruitment was terminated at 3 years despite the lower than planned sample size due to 
financial constraints. Of the remaining 447 participants, there were 201 controls and 246 
donors. Of these, a total of 38 controls and 46 donors were patients that originally consented 
into the CRIB-DONOR sub study, who re-consented to allow their data to be included.(26) 
One hundred and forty-one participants were unable to attend follow up at 12 months leaving 
168 donors and 138 controls with complete paired data, who were included in the final analysis. 
The commonest reasons for lack of study completion by participants were change of address 
or difficulty attending clinic visits due to travel distance, work and childcare commitments.  
For comparison between patients who were lost to follow up and those who continued in the 
study, see Table S1. Minimal differences were observed in those who did not return for follow 
up at 12 months. Participants who continued in the study, had a marginally lower eGFR and 
were more likely to be taking anti-hypertensive medications. 
In addition, a further 49 donors and 27 controls who returned for follow up had incomplete 
ambulatory blood pressure recordings.  
Patient characteristics 
The demographics of living kidney donors and healthy controls who attended for both 
baseline and 12 month follow up visits were comparable with the exception of tobacco use, 
see Table 1. Baseline hemodynamic and biochemical characteristics are shown in Tables 2 
and 3. There were no significant differences between donors and controls in any of the 
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baseline hemodynamic values and no clinically significant differences in biochemical values. 
At follow up there were 6 living kidney donors whose eGFR fell into stage 3b CKD and one 
whose eGFR fell into stage 4 CKD according to the Kidney Disease Improving Global 
Outcome guidelines.  
Patient demographics and hemodynamic and biochemical characteristics at baseline for all 
those recruited (n=447) are shown in supplementary Tables S2 and S3. Donors had a higher 
mean age than controls; (51 yrs. vs 47 yrs., p=0.003) and were more likely to have a history 
of previous smoking; (46% vs. 33%, p=0.007). 
Comparison of hemodynamic variables in living kidney donors and controls 
Arterial hemodynamic parameters at baseline and 12 months are given in Table 2. There were 
no significant differences between donors and controls in office or ambulatory blood pressures 
at 12 months. The changes in office systolic blood pressure from baseline to 12 months in 
donors and controls were small. The mean change seen in donors (+1.8mmHg) was however, 
different to that in controls, in whom there was a mean reduction of 1mmHg (difference of 
2.8mmHg, 95% confidence interval (CI) 0.3-5.4, p=0.03). Using current American Heart 
Association ambulatory blood pressure criteria, 13 (9%) in the control group and 15 (9%) in 
the donor group developed hypertension over the 12 month period with no significant 
difference between the two groups, p=0.18.(27) The mean change in ambulatory heart rate was 
significantly greater in donors compared to controls at 12 months (difference of 2.8 bpm, 95% 
CI 0.1-5.5, p=0.04).  
Adjusted pulse wave velocity was not significantly different at 12 months nor was there any 
difference in changes from baseline. Our supplementary analyses showed no association 
between kidney donation and change in pulse wave velocity when accounting for factors which 
may influence this relationship, see Table S4. Change in central diastolic blood pressure and 
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augmentation index adjusted for heart rate were not significantly different in donors compared 
to controls.  When considering changes from baseline, only central systolic blood pressure 
changes were significantly greater in donors than controls (difference of 3.3mmHg, 95% CI 
0.3, 6.3, p=0.03).  
Comparison of biochemistry in living kidney donors and controls 
Results are shown in Table 3. At 12 months, eGFR fell by a mean of 27mL/min/1.73m2 in 
donors but was unchanged in controls. Although iGFR measurement was part of the protocol 
for donation, in practice few subjects consented to a 12 month iGFR due to concerns about the 
duration of the test and exposure to ionising radiation.  The mean change from baseline for 
phosphate in donors was significantly lower compared to controls (difference -0.31 mg/dL, 
95% CI -0.31, -0.1, p=<0.001. In contrast a significant increase in uric acid was seen in donors 
compared to controls (difference 0.9 mg/dL, 95% CI 0.7, 1.0, p=<0.001). 
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Discussion  
This prospective study of ambulatory blood pressure monitoring and arterial hemodynamics in 
kidney donors provides important findings. There was no difference in office or ambulatory 
blood pressure in donors compared to controls at 12 months after nephrectomy. Pulse wave 
velocity also did not differ in these groups. Central systolic blood pressure increased slightly 
more in donors than controls and at 12 months was higher in the donor group. These results 
suggest that the risk of a significant rise in blood pressure at 12 months in kidney donors is 
small. This is in keeping with findings from the smaller sub-study CRIB-DONOR but is 
surprising in view of the high prevalence of hypertension in patients with CKD and similar 
levels of GFR.(26) Our data suggest that a simple loss of nephron numbers does not invariably 
result in an elevated blood pressure and that other aspects of CKD such as inflammation and 
nephron dysfunction may be required for this key pathophysiological mediator to occur.   
Previous data have been contradictory. In a 2006 meta-analysis of 48 studies of office blood 
pressure in kidney donors, including a total of 5145 patients, there was an increase in systolic 
blood pressure of 6 (95% CI 2-11) mmHg and an increase in diastolic pressure of 4 (95% CI 
1-7) mmHg in donors at 5 years.(28) More recently however, Kasiske et al. found no significant 
difference in over 300 participants between kidney donors and controls in office blood pressure 
at any time point up to 36 months.(29) There was also no difference in ambulatory blood 
pressure in 135 donors and 126 controls at 36 months.(29) Taken together, our data and the 
study of Kasiske et al. suggest that the risk of a clinically important change in blood pressure 
in the short term following kidney donation is low.(29) Longer term data are of course required.  
Despite the absence of change in peripheral pressure, the mean change in central systolic 
pressure was greater in donors at 12 months compared to controls (+ 2.1 vs-1.2mmHg, p=0.03). 
While this small difference may be a chance result due to multiple comparisons it may be 
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important as central blood pressure is better related to left ventricular mass, carotid intimal 
thickness and cardiovascular events than peripheral pressure.(30, 31) The small increase in AIx 
was not accompanied by any rise in pulse wave velocity. Discrepancies between changes in 
Aix and pulse wave velocity have been found by other observers in a number of situations and 
remain incompletely explained.(32) Any increase in AIx suggests an increase in wave 
reflection which might explain the increase in central blood pressure. As pulse wave velocity 
was unchanged it is possible that this increased reflection occurred due to changes in peripheral, 
rather than central arterial stiffness. We speculate that this occurred as a consequence of 
ligation of one of the renal arteries causing amplification of the reflection site without a 
corresponding change in pulse wave velocity, although to date this has no supportive animal 
or human evidence. Previous studies examining arterial stiffness in kidney donors have been 
small and uncontrolled. De-Seigneux et al. studied 21 patients before and one year after 
nephrectomy and found no change in AIx or pulse wave velocity.(33)  Similarly Fesler et al. 
found no change in pulse wave velocity at 12 months post nephrectomy in 45 donors.(34) A 
cross sectional study of 101 living kidney donors, however, found that pulse wave velocity was 
10% higher than control patients.(35) We cannot exclude a small effect on pulse wave velocity, 
as the study was not powered to detect a difference of less than 0.4m/s.  
Most of the biochemical changes after donation are in accord with previous studies (26, 29) 
Our finding of lower phosphate levels in donors is perhaps surprising in view of the renal 
excretion of phosphate but is consistent with a large prospective study of bone metabolism in 
kidney donors.(36) We speculate that this is a result of an increase in fibroblast growth factor 
23 which has a pivotal role in phosphate homeostasis and has been associated with left 
ventricular hypertrophy.(37, 38)  
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Conclusions 
In summary, this is the largest controlled longitudinal prospective study of hemodynamics in 
living kidney donors. This study indicates there is no change in ambulatory blood pressure or 
arterial stiffness at 12 months post nephrectomy despite changes in biochemistry. This has 
important implications for the future of living kidney donors but also provides valuable insight 
into the pathophysiology of hypertension and myocardial disease in CKD suggesting that an 
increase in blood pressure is not an inevitable consequence of a reduced GFR.  
Limitations 
We did not reach the planned sample size and a substantial proportion of participants did not 
return for follow up at one year, which limited the study power and introduces the potential for 
selection bias. Barriers to studies of living kidney donors have been reported by others.(39) 
They are often geographically remote from the transplant center (in contrast to the recipient) 
and after donation are usually in full time work. Barriers to ambulatory blood pressure 
monitoring in this study were in keeping with those previously observed, where one in five 
patients describe 24-hr monitoring as uncomfortable and nearly 70% are woken from sleep.(40, 
41)  
These limitations however, do not affect the internal validity of our results. There were only 
minor differences between participants who did and did not return for follow-up so our results 
should be generalizable to the wider pool of potential kidney donors. Although not statistically 
different, the healthy controls were on average 2 years younger, more likely to be male and 
more likely to have a history of hypertension. There was a greater rate of smoking amongst 
donors which could be due to in part to social deprivation based on geographical area or reflect 
health promoting behaviour in healthy controls.  In addition, the large number of parameters 
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measured beyond the pre-specified primary end-points mean that there are issues of multiple 
testing necessitating caution in interpreting results as some differences may have arisen by 
chance. 
Lack of ethnic diversity has been a notable problem in living kidney donor research.(7) Over 
90% of our cohort were Caucasian and this does reflect the vast racial disparity currently facing 
transplantation.(42) We recognise that while our data at 12 months are reassuring, longer term 
and more diverse studies are required particularly in light of literature showing higher 
cardiovascular risk in the long term.(8)  
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Figure 1: A typical aortic pulse wave form generated from applanation tonometry of the radial 
artery using the SphygmaCor, taken from Stoner et al (43). The maximum pressure is systolic 
and the minimum pressure is diastolic. The first peak, the forward wave, indicates ejected blood 
from the heart. The second peak, the reflected wave, is that returned from peripheral 
vasculature. The difference between the two is augmentation pressure. Augmentation index is 
augmentation pressure expressed as a percentage of pulse pressure. As augmentation index is 
influenced by timing of the reflected wave, augmentation index is corrected for a heart rate of 
75 beats per minute.  
 
Figure 2: A flow chart demonstrating those recruited and those lost to follow up.  
 
*Following eligibility assessment there were 22 patients who consented to take part but were ultimately 
excluded from the study. After baseline blood tests two ‘healthy controls’ did not meet criteria due to incidental 
findings; one was diagnosed with diabetes and one had an insufficient kidney function. Consequently, neither 
met living kidney donation criteria.  A further 20 patients consented to take part and withdrew prior to 
completing baseline assessment. This was usually because of competing appointments during living kidney 
donor work up.  
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Table 1:  Baseline characteristics of participants in the EARNEST study (Effect of A 
Reduction in glomerular filtration rate after NEphrectomy on arterial STiffness and central 
hemodynamics) who completed both baseline and 12-month evaluations. 
 Controls 
n=138 
Donors 
n=168 
Sex (male) * 
 
 
57 (41) 78 (46) 
Age (years) * 
 
 
49 ± 14 51 ± 12 
Race Caucasian=127 (92) 
Non-white=8 (6) 
Unknown=3 (2) 
Caucasian=158 (94) 
Non-white= 9 (5) 
Unknown= 1 (1) 
 
History of hypertension 
 
 
9 (7) 
 
17 (10) 
 
Anti-hypertensive usage* 
 
 
 
9 (7) 
 
18 (11) 
ACE/ARB usage 
 
4 (3) 5 (3) 
 
Calcium channel blocker usage 
 
 
4 (3) 
 
6 (4) 
 
Current or ex-smoker * 
 
 
 
38 (28) 
 
74 (44) 
eGFR, categories 
(mL/min/1.73m2) 
 
<80= 25 (18) 
80 to <90= 23 (17) 
>90 =88 (65) 
<80= 38 (23) 
80 to <90= 39 (23) 
>90= 91 (54) 
 
Normalised isotopic GFR 
(ml/min/1.73m2)* 
 
 
 
89 ± 13 
 
89 ± 12 
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ACE; Angiotensin Converting Enzyme. ARB; Angiotensin receptor blocker. CKD; Chronic 
Kidney Disease. eGFR; estimated Glomerular Filtration Rate. GFR; Glomerular Filtration 
Rate.  
 
*For the following categories: sex, age, anti-hypertensive usage and current or ex-smoker 
there were n=168 donors and n=137 controls due to an incomplete data set for one healthy 
control. For isotopic GFR, results from controls were part of the CRIB-DONOR sub study 
and included n=90 donors and n=22 controls.  
Categorical variables are presented as n (%) and continuous data are represented as mean ± 
standard deviation. 
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Table 2: Changes in hemodynamic and arterial parameters over 12 months. 
 
Variables Patient group Single Time point Change 
 n=sample size Baseline 12 months Within-group*  Between-group†  p-Value ‡ 
 
Weight (kg) 
Donors=168 75.4 ± 13.5 77.1 ± 14.7 1.7 (0.4, 3.0) 
 
 
 
1.5 (-0.12, 3.0) 
 
Controls=136 
 
74.7 ± 13.9 74.9 ± 13.8 0.2 (-0.4, 0.8) 0.07 
     
BMI (kg/m2) Donors=168 
 
26.2 ± 3.3 26.8 ± 4.6 0.6 (0.1, 1.2)  
 
0.5 (-0.1, 1.1) 
 
 Controls=136 
 
26.0 ± 4.0 26.2 ± 4.0 0.1 (-0.1, 0.3) 0.09 
      
Seated office 
systolic BP 
(mmHg) 
Donors=168 125 ± 14 
 
127 ± 12 
 
1.8 (-0.0, 3.6) 
 
 
 
2.8 (0.3, 5.4) 
 
Controls=135 
 
125 ±17 124 ± 17 -1.0 (-2.8, 0.7) 0.03 
     
Seated office 
diastolic BP 
(mmHg) 
Donors=168 78 ± 9 
 
80 ± 8 
 
1.7 (0.4, 2.9) 
 
 
 
1.0 (-0.74, 2.9) 
 
Controls=135 
 
77 ±10 78± 9 0.7 (-0.8, 1.9) 0.25 
     
Ambulatory 
day systolic 
BP (mmHg) 
Donors=119 
 
124 ± 10 124 ± 10 
 
0.1 (-1.7, 1.9)  
 
 -0.5 (-2.8, 1.7) 
 
Controls=111 
 
122 ± 10  123 ± 12 0.6 (-0.7, 2.0) 0.62 
     
Ambulatory 
day diastolic 
BP (mmHg) 
Donors=119 
 
79 ± 8  
 
79 ± 8 
 
0.2 (-0.9,1.4) 
 
 
 
 -0.6 (-2.1, 0.9) 
 
Controls=111 
 
77 ± 8 78 ± 9 0.9 (0.0, 1.7) 0.40 
     
Ambulatory 
day HR (bpm) 
Donors=65 
 
73 ± 9 
 
74 ± 10 
 
1.5 (-0.9, 3.9) 
 
 
 
2.8 (0.1, 5.5) 
 
Controls=82 
 
72 ± 9 71 ± 10 -1.3 (-2.8, 0.2) 0.04 
     
Ambulatory 
night systolic 
BP (mmHg) 
Donors=111 
 
111 ± 11  
 
112 ±11  
 
0.9 (-1.1, 3.0) 
 
 
 
 1.5 (-1.2, 4.3) 
 
Controls=105 
 
110 ± 10 110 ±12 -0.6 (-2.5,1.3) 0.27 
     
Ambulatory 
night diastolic 
BP (mmHg) 
Donors=111 
 
 67 ± 9 
 
69 ± 9 
 
 1.4 (-0.2, 3.0 ) 
 
 
 
 1.1 (-0.9, 3.3) 
 
Controls=105  66 ± 8  66 ± 9 0.3 (-1.15, 1.7) 0.27 
37 
 
 
     
Central 
systolic BP 
(mmHg) 
Donors=105 
 
113 ± 14 
 
115 ± 14 
 
2.1 (-0.2, 4.4) 
 
 
 
3.3 (0.3, 6.3) 
 
Controls=108 111 ± 17 109 ± 17 -1.2 (-3.1, 0.7) 0.03 
      
Central 
diastolic BP 
(mmHg) 
Donors=105 
 
77 ± 9 
 
78 ± 10 
 
1.3 (-0.7, 3.2) 
 
 
 
1.5 (-0.9, 4.0) 
 
Controls=108 
 
75 ± 10 75 ± 10 -0.3 (-1.9, 1.1) 0.22 
     
Augmentation 
index, 
corrected for 
HR (%) 
 
Donors=104 
 
22.1 ± 12.0 
 
25.6 ± 12.2 
 
3.4 (1.5, 5.3) 
 
 
 
1.6 (-1.0, 4.2) 
 
Controls=108 20.4 ±12.5 22.3 ± 12.0 1.8 (-0.0, 3.6) 0.23 
      
Adjusted 
carotid-
femoral pulse 
wave velocity 
(m/s) 
Donors=168 
 
7.0 ± 1.3 
 
7.3  ± 1.4 
 
0.3 (0.1, 0.4) 
 
 
 
0.1 (-0.2, 0.3) 
 
Controls=138 
 
7.0 ± 1.4 7.2 ±1.4                                          0.2 (-0.0, 0.4) 0.49 
     
 
BPM; Beats per minute. BMI; Body mass index. BP; Blood Pressure, CI; Confidence 
interval, HR: Heart rate, SD: Standard deviation. 
Data is displayed as mean ± SD or mean (95% lower CI, 95% upper CI). 
* Within-group change refers to change in values between baseline and follow up in each 
group i.e. mean weight in donors for baseline was 75.4 kg and at follow up was 77.1 kg 
giving a within-group change of 1.7kg. The 95% confidence interval was estimated using 
paired sample t-tests. 
† Between-group change refers to the difference between donors and controls within-group 
change i.e. for weight, within group change for donors is 1.7kg and 0.2kg for controls giving 
a between group-change of 1.5kg. The 95% confidence interval was estimated using 
independent t-tests. 
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‡ Comparison between controls and donors was made for within-group change [i.e. mean 
change in weight in donors (1.7kg) vs mean change in weight in controls (0.2kg)] using an 
independent samples t-tests. 
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Table 3: Changes in biochemical parameters over 12 months. 
Variables Patient 
group 
Single time point Change 
 n=sample 
size 
Baseline 12 months Within-group*  Between-group†     p-Value ‡ 
Sodium 
(meq/L) 
Donors=167 
 
140 ± 2 
 
140 ± 2 
 
-0.3 (-0.7, 0.0) 
 
 
 
-0.1 (-0.6, 0.4) 
 
 
0.59 
Controls=137 141 ± 2 140  ± 2 -0.2 (-0.5, 0.2)  
     
Potassium 
(meq/L) 
 
Donors=167 
 
4.3 ± 0.3 
 
4.4 ± 0.4 
 
0.1 (0.0, 0.2) 
 
 
 
0.1 (0.0, 0.2) 
 
Controls=134 4.2 ± 0.3 4.2 ± 0.3 
 
-0.0 (-0.1, 0.1) 
 
0.02 
     
Urea (mg/dL) 
 
Donors=167 
 
31 ± 8 
 
38 ± 10 
 
8.4 (7.2, 9.6) 
 
 
 
7.2 (5.4, 9.0) 
 
Controls=136 
 
30 ± 8 31 ± 8 
 
1.0 (0.03, 2.4) <0.001 
     
Creatinine 
(mg/dL) 
Donors=168 
 
0.8  ± 0.2 
 
1.2  ± 0.2 
 
0.3 (0.3, 0.4) 
 
 
 
0.3 (0.3, 0.4) 
 
Controls=136 
 
0.8  ± 0.2 0.8  ± 0.2 -0.02 (-0.03, 0.009) <0.001 
     
eGFR 
(mL/min/1.73
m2) 
Donors=168 
 
91 ± 15 
 
64 ± 14 
 
-27 (-29, -26) 
 
 
 
-29 (-32, -26) 
 
 
<0.001 
Controls=136 94 ± 16 96 ± 17 2 (-0.4, 3.8)  
     
Albumin 
(g/dL) 
 
Donors=145 
 
4.27  ±  0.39 
 
4.22  ±  0.43 
 
-0.04 (-0.10, 0.01) 
 
 
 
-0.07 (-0.15, -0.0) 
 
Controls=135 4.16 ± 0.44 
 
4.19 ± 0.48 
 
0.03 (-0.01, 0.08) 0.04 
     
Corrected 
calcium 
(mg/dL) 
 
Donors=148 
 
9.2 ± 0.4 
 
9.2  ± 0.4  
 
0.0 (-0.0, 0.0) 
 
 
 
-0.0 (-0.0 – 0.0) 
 
Controls=136 9.2 ± 0.4 9.2  ± 0.4 0.0 (-0.0, 0.0) 
 
0.28 
     
Phosphate, 
(mg/dL) 
Donors=130 
 
3.4  ±  0.6 
 
3.1  ± 0.6 
 
-0.3 (-0.3, -0.3) 
 
 
 
-0.31 (-0.31, -0.1) 
 
Controls=121 3.4  ±  0.6 3.4  ± 0.6 0.0 (-0.0, 0.3) <0.001 
     
Magnesium, Donors=77 
 
2.2  ± 1.7 
 
2.2 ± 0.2 
 
0.0 (-0.0, 0.0) 
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(mg/dL) 
 
Controls=85 2.2  ± 1.7 
 
2.2  ± 0.2 
 
0.0 (-0.0,  0.0) 
 
-0.0 (-0.0- 0.0) 0.94 
     
Uric acid 
(mg/dL) 
 
Donors=93 
 
5.0  ± 1.2 
 
5.9  ± 1.3 
 
0.9 (0.69, 1.0) 
 
 
 
0.9 (0.7, 1.0) 
 
 
<0.001 
Controls=95 4.8  ± 1.1 4.8  ± 1.1 -0.0 (-0.6, 0.1)  
     
Urine 
albumin: 
creatinine 
ratio 
(mg/mmol) 
Donors=66 
 
24.6  ± 41.2 
 
23.1  ± 39.8 
 
-1.5 (-9.7, 7.1) 
 
 
 
-1.5 (-9.7, 12.4) 
 
Controls=69 
 
20.1  ± 32.7 17.1  ± 32.0 -3.0 (-11.5, 5.3) 0.80 
      
 
CI; Confidence interval, eGFR; estimated glomerular filtration rate, SD: Standard deviation. 
Data is displayed as mean ± SD or mean (95% lower CI-95% upper CI). 
* Within-group change refers to change in values between baseline and follow up in each 
group i.e. mean potassium in donors for baseline was 4.3 meq/L and at follow up was 4.4 
meq/L giving a within-group change of 0.1 meq/L. The 95% confidence interval was 
estimated using paired sample t-tests. 
† Between-group change refers to the difference between donors and controls within-group 
change i.e. for potassium, within group change for donors is 0.1 meq/L and 0.0 meq/L for 
controls giving a between group-change of 0.1 meq/L. The 95% confidence interval was 
estimated using independent t-tests. 
‡ Comparison between controls and donors was made for within-group change [i.e. mean 
change in potassium in donors (0.1 meq/L) vs mean change in weight in controls (0.0 meq/L 
)] using an independent samples t-tests. 
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